1160939-75-2

Upstream product

• 1160939-72-9 3,5-diamino-6-chloropyrazine-2-carboxylic acid [(S)-4-(3-aminopropyl)-imidazolidin-(2E)-ylidene]amide 
• 103-80-0 phenylacetyl chloride 
• 775530-61-5 3,5-diamino-6-chloro-N-[(methylsulfanyl)methanimidoyl]pyrazine-2-carboxamide 
• 1160755-10-1 ((S)-4,5-diaminopentyl)carbamic acid benzyl ester 
• 1160939-71-8 (3-{(S)-2-[(E)-3,5-diamino-6-chloropyrazine-2-carbonylimino]imidazolidin-4-yl}propyl)carbamic acid benzyl ester 
• 62631-17-8 Methyl N-δ-benzyloxycarbonyl-L-ornithinate 
• 1160755-11-2 ((S)-4-amino-4-carbamoylbutyl)carbamic acid benzyl ester 

Relevant academic research and scientific papers

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Organic Compounds

A compound of Formula I in free or salt or solvate form, where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.